Rigel Pharmaceuticals RIGL EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's EPS (diluted)?
- Rigel Pharmaceuticals (RIGL) reported EPS (diluted) of $0.44 in Q1 2026.
- How has Rigel Pharmaceuticals's EPS (diluted) changed year-over-year?
- Rigel Pharmaceuticals's EPS (diluted) decreased by 30.2% year-over-year, from $0.63 to $0.44.
- What is the long-term trend for Rigel Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's EPS (diluted) has grown at a 256.9% compound annual growth rate (CAGR), from -$0.12 to $19.47.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.